Methods: The study included 28 eyes of 28 patients with neovascular AMD who had at least 6 months of follow-up following 3-dose anti- VEGF injection. Central macular thickness (CMT) and GCC thickness were evaluated with SD-OCT. Visual acuity, intraocular pressure, CMT, GCC thickness were recorded at the fi rst month, 3 months and 6 months after the injection.

Results: The mean age of the patients was 71.9 ± 7.2 (55-82) years. Best corrected visual acuity (logMAR) before injection was 0.90±0.24, at third month it was 0.32±0.22 idi (p=0.005). Before injection the mean CMT was 383.75 ± 28.6 ?m, it was 267 ± 67 ?m in the 6th month (p = 0.001). Mean GCC thickness was 93.20 ?m before injection and 92.56 ?m at 6 months. (P = 0.250)

Conclusion: It was found that intravitreal Afl ibercept injection did not have a signifi cant effect on GCC thickness after 6 months of follow-up. Afl ibercept is an effective, reliable treatment option in the treatment of neovascular AMD. Keywords : Aflibercept, Neovascular AMD, Ganglion cell complex